E J T Rutgers

Summary

Affiliation: The Netherlands Cancer Institute
Country: The Netherlands

Publications

  1. doi request reprint Sentinel node biopsy: interpretation and management of patients with immunohistochemistry-positive sentinel nodes and those with micrometastases
    Emiel J T Rutgers
    Department of Surgery, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    J Clin Oncol 26:698-702. 2008
  2. pmc Scenario drafting to anticipate future developments in technology assessment
    Valesca P Retel
    Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital NKI AVL, Department of Psychosocial Research and Epidemiology, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands
    BMC Res Notes 5:442. 2012
  3. pmc A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples
    Wilbert Zwart
    Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge, UK
    BMC Genomics 14:232. 2013
  4. pmc Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial
    Sepideh Saadatmand
    Department of Surgery, Erasmus University Medical Centre, Rotterdam, Netherlands
    BMC Cancer 12:440. 2012
  5. ncbi request reprint [How can breast-conserving surgery be improved even more?]
    Emiel J T Rutgers
    Nederlands Kanker Instituut Antoni van Leeuwenhoek Ziekenhuis, afd Heelkunde, Amsterdam, The Netherlands
    Ned Tijdschr Geneeskd 156:A5202. 2012
  6. pmc SUBMIT: Systemic therapy with or without up front surgery of the primary tumor in breast cancer patients with distant metastases at initial presentation
    Jetske Ruiterkamp
    Department of Surgery, Maxima Medical Center, Veldhoven, The Netherlands
    BMC Surg 12:5. 2012
  7. pmc Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter randomized clinical trial
    Marijke R Wevers
    Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, PO Box 90203, 1006 BE Amsterdam, The Netherlands
    BMC Cancer 11:6. 2011
  8. pmc Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial
    Marieke E Straver
    Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Ann Surg Oncol 17:1854-61. 2010
  9. ncbi request reprint Sentinel node procedure in breast carcinoma: a valid tool to omit unnecessary axillary treatment or even more?
    E J T Rutgers
    Department of Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek ziekenhuis, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Eur J Cancer 40:182-6. 2004
  10. ncbi request reprint Guidelines to assure quality in breast cancer surgery
    E J Th Rutgers
    Department of Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Eur J Surg Oncol 31:568-76. 2005

Collaborators

Detail Information

Publications39

  1. doi request reprint Sentinel node biopsy: interpretation and management of patients with immunohistochemistry-positive sentinel nodes and those with micrometastases
    Emiel J T Rutgers
    Department of Surgery, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    J Clin Oncol 26:698-702. 2008
    ..Protocols that identify lymph node metastasis, from which the clinical relevance is known, are warranted. Unnecessary lymph node dissections should be avoided...
  2. pmc Scenario drafting to anticipate future developments in technology assessment
    Valesca P Retel
    Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital NKI AVL, Department of Psychosocial Research and Epidemiology, Plesmanlaan 121, Amsterdam 1066 CX, The Netherlands
    BMC Res Notes 5:442. 2012
    ..Secondly, we explored the value of this method on the case of the clinical implementation of the 70-gene signature for breast cancer, a gene expression profile for selecting patients who will benefit most from chemotherapy...
  3. pmc A carrier-assisted ChIP-seq method for estrogen receptor-chromatin interactions from breast cancer core needle biopsy samples
    Wilbert Zwart
    Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, Robinson Way, Cambridge, UK
    BMC Genomics 14:232. 2013
    ....
  4. pmc Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial
    Sepideh Saadatmand
    Department of Surgery, Erasmus University Medical Centre, Rotterdam, Netherlands
    BMC Cancer 12:440. 2012
    ..The aim of the Familial MRI Screening Study (FaMRIsc) is to compare the efficacy of MRI screening to mammography for women with a familial risk. Furthermore, we will assess the influence of breast density...
  5. ncbi request reprint [How can breast-conserving surgery be improved even more?]
    Emiel J T Rutgers
    Nederlands Kanker Instituut Antoni van Leeuwenhoek Ziekenhuis, afd Heelkunde, Amsterdam, The Netherlands
    Ned Tijdschr Geneeskd 156:A5202. 2012
    ..Generally speaking, ultrasound-guided breast-conserving resection of invasive breast cancer may well lead to more initially complete resections and better cosmetic results...
  6. pmc SUBMIT: Systemic therapy with or without up front surgery of the primary tumor in breast cancer patients with distant metastases at initial presentation
    Jetske Ruiterkamp
    Department of Surgery, Maxima Medical Center, Veldhoven, The Netherlands
    BMC Surg 12:5. 2012
    ..Therefore, a randomized controlled trial will be performed to assess whether breast surgery in patients with primary distant metastatic breast cancer will improve the prognosis...
  7. pmc Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter randomized clinical trial
    Marijke R Wevers
    Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute, PO Box 90203, 1006 BE Amsterdam, The Netherlands
    BMC Cancer 11:6. 2011
    ..The aim of this study is to determine the effect of RGCT on treatment decisions and on psychosocial health...
  8. pmc Sentinel node identification rate and nodal involvement in the EORTC 10981-22023 AMAROS trial
    Marieke E Straver
    Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Ann Surg Oncol 17:1854-61. 2010
    ..The aim of the current substudy was to evaluate the identification rate and the nodal involvement...
  9. ncbi request reprint Sentinel node procedure in breast carcinoma: a valid tool to omit unnecessary axillary treatment or even more?
    E J T Rutgers
    Department of Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek ziekenhuis, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Eur J Cancer 40:182-6. 2004
  10. ncbi request reprint Guidelines to assure quality in breast cancer surgery
    E J Th Rutgers
    Department of Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Eur J Surg Oncol 31:568-76. 2005
    ..The outcome of the different procedures can be measured according to simple criteria and prospective registration. All possible surgical procedures, the indication-objectives, the training-objectives and outcome measures are described...
  11. ncbi request reprint Sentinel node micrometastasis in breast cancer
    E J T Rutgers
    Department of Surgery, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Br J Surg 91:1241-2. 2004
  12. ncbi request reprint Follow-up care in breast cancer
    Emiel J Rutgers
    Department of Surgery, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Expert Rev Anticancer Ther 4:212-8. 2004
    ..For more complex issues, such as debilitating functional treatment regimens, estrogen deprivation symptoms, pregnancy after breast cancer or symptoms suspicious for a relapse, an experienced oncologist should be at hand...
  13. pmc Clinical trials update of the European Organization for Research and Treatment of Cancer Breast Cancer Group
    Emiel J T Rutgers
    Department of Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Breast Cancer Res 6:165-9. 2004
    ....
  14. ncbi request reprint Ductal carcinoma in situ of the breast; diagnostic assessment and treatment
    E J Th Rutgers
    Department of Surgery, Pathology, and Radiation Oncology, Netherlands Cancer Institute, Amsterdam
    Scand J Surg 91:268-72. 2002
  15. doi request reprint The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase
    Emiel Rutgers
    The Netherlands Cancer Institute, Department of Surgery, Amsterdam, The Netherlands
    Eur J Cancer 47:2742-9. 2011
    ..We present the results of the pilot phase consisting of first 800 patients included...
  16. ncbi request reprint Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy
    P Meijnen
    Department of Surgery, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Br J Surg 94:952-6. 2007
    ..The data were used to select criteria for patients in whom sentinel node (SN) biopsy might be indicated...
  17. ncbi request reprint Excision biopsy of breast lesions changes the pattern of lymphatic drainage
    S H Estourgie
    Department of Surgery, Academic Medical Centre, Meibergdreef 9, Amsterdam, The Netherlands
    Br J Surg 94:1088-91. 2007
    ..The aim was to validate the sentinel node biopsy procedure in women who had previous breast excision biopsy by means of determining the reproducibility of lymphoscintigraphy after surgery...
  18. doi request reprint Marking the axilla with radioactive iodine seeds (MARI procedure) may reduce the need for axillary dissection after neoadjuvant chemotherapy for breast cancer
    M E Straver
    Department of Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands
    Br J Surg 97:1226-31. 2010
    ..The aim was to assess a new surgical method for evaluating the axillary response to chemotherapy...
  19. pmc A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study
    C A Drukker
    Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
    Int J Cancer 133:929-36. 2013
    ..Omission of adjuvant chemotherapy as judged appropriate by doctors and patients and instigated by a low-risk 70-gene signature result, appeared not to compromise outcome...
  20. doi request reprint The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age
    S Mook
    Department of Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, The Netherlands
    Ann Oncol 21:717-22. 2010
    ..The aim of this study was to evaluate the prognostic value of the 70-gene prognosis signature for early events in postmenopausal patients...
  21. doi request reprint Validation of 70-gene prognosis signature in node-negative breast cancer
    J M Bueno-de-Mesquita
    Department of Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands
    Breast Cancer Res Treat 117:483-95. 2009
    ....
  22. ncbi request reprint Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up
    J G Schrama
    Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam
    Ann Oncol 13:689-98. 2002
    ....
  23. ncbi request reprint Stage of breast cancers found during the surveillance of women with a familial or hereditary risk
    R Kaas
    Department of Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands
    Eur J Surg Oncol 34:501-7. 2008
    ..To compare the breast cancer stages found during MG alone surveillance in women at increased risk with those detected in a program where MRI was added...
  24. ncbi request reprint The hidden sentinel node in breast cancer
    P J Tanis
    Department of Surgery, The Netherlands Cancer Institute, Amsterdam
    Eur J Nucl Med Mol Imaging 29:305-11. 2002
    ..Delayed imaging and re-injection of the radioactive tracer increase the visualisation rate. The non-visualised sentinel node can be identified intraoperatively in more than half of the patients...
  25. pmc Effects of patient selection on the applicability of results from a randomised clinical trial (EORTC 10853) investigating breast-conserving therapy for DCIS
    N Bijker
    Department of Radiation Oncology, The Netherlands Cancer Institute Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Br J Cancer 87:615-20. 2002
    ..Selection of patients may explain the differences in outcome of the randomised patients, and those not-entered. Thus, the results of this trial may not be applicable to all patients with ductal carcinoma in situ...
  26. pmc The influence of tamoxifen treatment on the oestrogen receptor in metachronous contralateral breast cancer
    R Kaas
    Department of Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek Ziekenhuis Plesmanlaan, Amsterdam, The Netherlands
    Br J Cancer 88:707-10. 2003
    ..045). In conclusion, metachronous CBCs developing after 1-3 years of tamoxifen treatment are more often ER-negative breast cancers. So far this does not seem to have a major impact on survival...
  27. pmc Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature
    M Knauer
    Division of Diagnostic Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, Amsterdam NL 1066CX, The Netherlands
    Br J Cancer 103:1788-93. 2010
    ..However, the majority of patients does not recur and might thus be overtreated with adjuvant systemic therapy. We investigated whether the 70-gene MammaPrint signature identifies HER-2-positive patients with favourable outcome...
  28. ncbi request reprint Adjuvant therapy for breast cancer
    S Rodenhuis
    Departments of Medical Oncology and Surgical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Br J Surg 93:1443-5. 2006
  29. doi request reprint Axillary and extra-axillary lymph node recurrences after a tumor-negative sentinel node biopsy for breast cancer using intralesional tracer administration
    Iris M C van der Ploeg
    Department of Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066, CX, Amsterdam, The Netherlands
    Ann Surg Oncol 15:1025-31. 2008
    ..The objective of the present study of sentinel node-negative breast cancer patients was to determine the lymph node recurrence rates in the axilla and elsewhere, the false-negative rates, and the survival...
  30. ncbi request reprint Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER)
    Jolien M Bueno-de-Mesquita
    Department of Pathology, Division of Diagnostic Oncology, Netherlands Cancer Institute, Amsterdam, Netherlands
    Lancet Oncol 8:1079-87. 2007
    ....
  31. ncbi request reprint Ultrasonography and fine-needle aspiration cytology can spare breast cancer patients unnecessary sentinel lymph node biopsy
    Maartje C van Rijk
    Department of Surgery, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, CX, 1066, The Netherlands
    Ann Surg Oncol 13:31-5. 2006
    ..The aims of this study were to evaluate the sensitivity of preoperative ultrasonography and fine-needle aspiration cytology for detecting axillary metastases and to assess how often sentinel node biopsy could be avoided...
  32. ncbi request reprint Sentinel node biopsy before neoadjuvant chemotherapy spares breast cancer patients axillary lymph node dissection
    Maartje C van Rijk
    Department of Surgery, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, CX, 1066, The Netherlands
    Ann Surg Oncol 13:475-9. 2006
    ..In our institute, sentinel lymph node biopsy is performed before neoadjuvant chemotherapy. The aim of this study was to evaluate our experience with this approach...
  33. ncbi request reprint Are short-term or long-term recurrence rates more important in breast cancer screening?
    Emiel J T Rutgers
    Ann Intern Med 149:357; author reply 357-8. 2008
  34. ncbi request reprint Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition
    Mieke Kriege
    The Rotterdam Family Cancer Clinic, Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, Netherlands
    Cancer 106:2318-26. 2006
    ....
  35. ncbi request reprint Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition
    Mieke Kriege
    Rotterdam Family Cancer Clinic, Department of Medical Oncology, Erasmus Medical Center Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    N Engl J Med 351:427-37. 2004
    ..We compared the efficacy of magnetic resonance imaging (MRI) with that of mammography for screening in this group of high-risk women...
  36. doi request reprint Effects of lycopene on the insulin-like growth factor (IGF) system in premenopausal breast cancer survivors and women at high familial breast cancer risk
    Dorien W Voskuil
    Division of Experimental Therapy and the Department of Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    Nutr Cancer 60:342-53. 2008
    ..However, lycopene effects were discordant between the 2 study populations showing beneficial effects in high-risk healthy women but not in breast cancer survivors...
  37. ncbi request reprint Individualization of therapy using Mammaprint: from development to the MINDACT Trial
    Stella Mook
    Netherlands Cancer Institute, Amsterdam, The Netherlands
    Cancer Genomics Proteomics 4:147-55. 2007
    ....
  38. ncbi request reprint Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer
    Mieke Kriege
    Family Cancer Clinic, Department of Medical Oncology, Erasmus MC Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    Breast Cancer Res Treat 100:109-19. 2006
    ..In the current subsequent study we investigated whether these results are influenced by age, a BRCA1/2 mutation, menopausal status and breast density...
  39. ncbi request reprint Prognostic factors and evaluation of surgical management of hepatic metastases from colorectal origin: a 10-year single-institute experience
    Eduard L A R Mutsaerts
    Department of Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands
    J Gastrointest Surg 9:178-86. 2005
    ..Our data suggest there is no strong predictor of survival. Survival seems to decrease with increasing number of metastases found on computed tomography...